Pregnancy outcomes of women who received conservative therapy for endometrial carcinoma or atypical endometrial hyperplasia
Abstract Case Approximately 3%‐25% of cases of endometrial carcinoma (EC) or atypical endometrial hyperplasia (AH) occur in women aged <40 years and conservative treatment with high‐dose medroxyprogesterone acetate (MPA) is administered to women who wish to preserve their fertility. Here is repor...
Egile Nagusiak: | Toshiya Matsuzaki, Takeshi Iwasa, Takako Kawakita, Yuri Yamamoto, Akiko Abe, Aki Hayashi, Kiyohito Yano, Masato Nishimura, Akira Kuwahara, Minoru Irahara |
---|---|
Formatua: | Artikulua |
Hizkuntza: | English |
Argitaratua: |
Wiley
2018-07-01
|
Saila: | Reproductive Medicine and Biology |
Gaiak: | |
Sarrera elektronikoa: | https://doi.org/10.1002/rmb2.12209 |
Antzeko izenburuak
-
Medroxyprogesterone Acetate Plus Metformin to Prevent Persistent Endometrial Hyperplasia
nork: Vakkas Korkmaz, et al.
Argitaratua: (2013-08-01) -
Results of surgical treatment of atypical endometrial hyperplasia
nork: O. A. Gornykh, et al.
Argitaratua: (2014-07-01) -
Modern approaches to the diagnosis of endometrial hyperplasia
nork: M. M. Damirov, et al.
Argitaratua: (2025-02-01) -
Microsatellite instability as a reliable marker of coexisting endometrial cancer in atypical endometrial hyperplasia
nork: А. E. Protasova, et al.
Argitaratua: (2024-07-01) -
Endometrial Atypical Hyperplasia and Risk of Endometrial Cancer
nork: An-Ju Chou, et al.
Argitaratua: (2024-11-01)